A leading pharmaceutical powerhouse renowned for innovative skincare solutions has unveiled its latest breakthrough in tackling facial hyperpigmentation. The groundbreaking serum, featuring a first-of-its-kind dual liposomal technology in India, promises enhanced skin penetration and superior results through its advanced formulation of carefully selected active ingredients.
Share Price Movement
The share price of Alkem Laboratories Limited went up 1.7 percent to Rs. 5,193.85 per share on Wednesday, an increase from its previous close of Rs. 5,105.90 per share. The market capitalisation now stands at approximately Rs. 61,268 crore as of February 05, 2025.
What Happened
Alkem introduces Kojiglo serum in India, featuring Duo-Lipo technology for enhanced skin penetration. It combines liposomal azelaic acid, 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide to effectively target hyperpigmentation while minimising skin irritation. They have claimed this is suitable for all skin types.
Financial Highlights
In Q2FY25, revenue stood at Rs. 3,415 crore, showing a slight YoY decline of 0.7% from Rs. 3,440 crore in Q2FY24 but a strong QoQ growth of 12.6% from Rs. 3,032 crore in Q1FY25. Profit for Q2FY25 was Rs. 702 crore, reflecting a 14.1% YoY increase from Rs. 615 crore in Q2FY24 and a 27.6% QoQ rise from Rs. 550 crore in Q1FY25. Q3 results are expected on 7 February 2025.
Competitors
Alkem Laboratories competes with major pharmaceutical players like Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Dr. Reddy’s Laboratories, Lupin, Aurobindo Pharma, and Zydus Cadila in the highly competitive pharmaceutical industry.
Alkem Laboratories is currently trading at a P/E of 28.25, which is above the industry P/E of 23.82.
Market Outlook
India’s pharmaceutical industry is growing rapidly, driven by cost efficiency, strong economic factors, and policy support. With affordable treatments and advanced technology, India is a global medical hub.
The sector is expected to reach $130 billion by 2030, supported by government schemes like PLI and SPI. Increasing FDI and a strong global presence further strengthen India’s position as the ‘Pharmacy of the World. Rising investments, exports, and manufacturing capabilities ensure continued growth and global competitiveness in the coming years.
